Should I start colorectal cancer screening at 45?

Share This Post

A new study reported at the European Digestive Disease Week (UEG) shows that regardless of family history, colorectal cancer screening has doubled since the age of 45 rather than 50. (UEG 2017)

The researchers pointed out that the general population of the colonoscopy screening program recommends screening for people over the age of 50, but the incidence of colorectal cancer under the age of 50 has increased.

This prospective study evaluated 6027 cases of colonoscopy. The detection rates of polyps, adenomas, large polyps and cancer were 34.0%, 32.0%, 8.0% and 3.6%, respectively. One of the more important findings of this study is that when the risk of adenoma and cancer detection is analyzed by different age groups, the detection rate of people under 30 years old is very low, and it is relatively low before 45 years old. There is a very significant increase.

The average polyp detection rate of 4438 patients over 50 years old was over 35%, and the cancer detection rate exceeded 5%. The average polyps detection rate of 515 patients aged 45-49 years was 26%, and the cancer detection rate was nearly 4%. The detection rate of 1076 subjects ≤44 years old was very low. Even after excluding high-risk populations with a family history, the detection rate of polyps or cancer was still high among people aged 45 to 49 years.

The researchers believe that the research population is a real practice population, so the research conclusions are applicable to the general screening population. 50-year-old should not be used as the starting age for screening, and colorectal cancer screening should be started from 45-year-old to better prevent colorectal cancer. The results of the study suggest that, even if there is no family history, the risk of disease will increase greatly after the age of 45, which is more critical. 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy